{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:02:08Z","timestamp":1785549728776,"version":"3.56.0"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1038\/s41585-020-00384-7","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T11:02:41Z","timestamp":1605006161000},"page":"679-690","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Surgical management of high-risk, localized prostate cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Lamont J.","family":"Wilkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Tosoian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasish","family":"Sundi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley E.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2289-4781","authenticated-orcid":false,"given":"Dominic","family":"Grimberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1783-0698","authenticated-orcid":false,"given":"Eric A.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian F.","family":"Chapin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8799-6749","authenticated-orcid":false,"given":"Yaw A.","family":"Nyame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,10]]},"reference":[{"key":"384_CR1","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.urology.2012.07.040","volume":"80","author":"AC Reese","year":"2012","unstructured":"Reese, A. C., Pierorazio, P. M., Han, M. & Partin, A. W. Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system. Urology 80, 1075\u20131079 (2012).","journal-title":"Urology"},{"key":"384_CR2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1200\/jco.2015.33.7_suppl.143","volume":"33","author":"MD Hall","year":"2015","unstructured":"Hall, M. D., Schultheiss, T. E., Farino, G. & Wong, J. Y. C. Increase in higher risk prostate cancer cases following new screening recommendation by the US preventive services task force (USPSTF). J. Clin. Oncol. 33, 143\u2013143 (2015).","journal-title":"J. Clin. Oncol."},{"key":"384_CR3","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/jama.2018.19941","volume":"321","author":"BA Mahal","year":"2019","unstructured":"Mahal, B. A. et al. Use of active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the United States, 2010\u20132015. JAMA 321, 704\u2013706 (2019).","journal-title":"JAMA"},{"key":"384_CR4","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eururo.2019.12.017","volume":"77","author":"JJ Tosoian","year":"2020","unstructured":"Tosoian, J. J. et al. Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort. Eur. Urol. 77, 675\u2013682 (2020).","journal-title":"Eur. Urol."},{"key":"384_CR5","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","volume":"33","author":"L Klotz","year":"2015","unstructured":"Klotz, L. et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J. Clin. Oncol. 33, 272\u2013277 (2015).","journal-title":"J. Clin. Oncol."},{"key":"384_CR6","first-page":"201","volume":"111","author":"PT Scardino","year":"2000","unstructured":"Scardino, P. T. The Gordon Wilson lecture. Natural history and treatment of early stage prostate cancer. Trans. Am. Clin. Climatol. Assoc. 111, 201\u2013241 (2000).","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"key":"384_CR7","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1001\/jama.293.17.2095","volume":"293","author":"PC Albertsen","year":"2005","unstructured":"Albertsen, P. C., Hanley, J. A. & Fine, J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293, 2095\u20132101 (2005).","journal-title":"JAMA"},{"key":"384_CR8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/cncr.31833","volume":"125","author":"D Sundi","year":"2019","unstructured":"Sundi, D. et al. Outcomes of very high-risk prostate cancer after radical prostatectomy: validation study from 3 centers. Cancer 125, 391\u2013397 (2019).","journal-title":"Cancer"},{"key":"384_CR9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.critrevonc.2016.04.011","volume":"102","author":"A Morlacco","year":"2016","unstructured":"Morlacco, A. & Karnes, R. J. High-risk prostate cancer: the role of surgical management. Crit. Rev. Oncol. Hematol. 102, 135\u2013143 (2016).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"384_CR10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(08)61815-2","volume":"373","author":"A Widmark","year":"2009","unstructured":"Widmark, A. et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7\/SFUO-3): an open randomised phase III trial. Lancet 373, 301\u2013308 (2009).","journal-title":"Lancet"},{"key":"384_CR11","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/S0140-6736(11)61095-7","volume":"378","author":"P Warde","year":"2011","unstructured":"Warde, P. et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 378, 2104\u20132111 (2011).","journal-title":"Lancet"},{"key":"384_CR12","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1200\/JCO.2014.57.8724","volume":"33","author":"M Brundage","year":"2015","unstructured":"Brundage, M. et al. Impact of radiotherapy when added to androgen-deprivation therapy for locally advanced prostate cancer: long-term quality-of-life outcomes from the NCIC CTG PR3\/MRC PR07 randomized trial. J. Clin. Oncol. 33, 2151\u20132157 (2015).","journal-title":"J. Clin. Oncol."},{"key":"384_CR13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jama.2015.6036","volume":"314","author":"MR Cooperberg","year":"2015","unstructured":"Cooperberg, M. R. & Carroll, P. R. Trends in management for patients with localized prostate cancer, 1990\u20132013. JAMA 314, 80\u201382 (2015).","journal-title":"JAMA"},{"key":"384_CR14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/pcan.2017.5","volume":"20","author":"AB Weiner","year":"2017","unstructured":"Weiner, A. B. et al. Contemporary management of men with high-risk localized prostate cancer in the United States. Prostate Cancer Prostatic Dis. 20, 283\u2013288 (2017).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"384_CR15","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.eururo.2016.08.047","volume":"71","author":"PJ Gray","year":"2017","unstructured":"Gray, P. J., Lin, C. C., Cooperberg, M. R., Jemal, A. & Efstathiou, J. A. Temporal trends and the impact of race, insurance, and socioeconomic status in the management of localized prostate cancer. Eur. Urol. 71, 729\u2013737 (2017).","journal-title":"Eur. Urol."},{"key":"384_CR16","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.eururo.2012.02.053","volume":"61","author":"M Alemozaffar","year":"2012","unstructured":"Alemozaffar, M. et al. Technical refinement and learning curve for attenuating neurapraxia during robotic-assisted radical prostatectomy to improve sexual function. Eur. Urol. 61, 1222\u20131228 (2012).","journal-title":"Eur. Urol."},{"key":"384_CR17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5489\/cuaj.3214","volume":"10","author":"A Almatar","year":"2016","unstructured":"Almatar, A. et al. Effect of radical prostatectomy surgeon volume on complication rates from a large population-based cohort. Can. Urol. Assoc. J. 10, 45\u201349 (2016).","journal-title":"Can. Urol. Assoc. J."},{"key":"384_CR18","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1200\/JCO.2016.34.15_suppl.1548","volume":"34","author":"AM Algotar","year":"2016","unstructured":"Algotar, A. M., Singh, P., Billins, J. & Thomazin, G. Change in prostate biopsy outcomes and costs of care for prostate cancer in underserved population after changes in USPSTF guidelines. J. Clin. Oncol. 34, 1548\u20131548 (2016).","journal-title":"J. Clin. Oncol."},{"key":"384_CR19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrurol.2016.251","volume":"14","author":"K Fleshner","year":"2017","unstructured":"Fleshner, K., Carlsson, S. V. & Roobol, M. J. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat. Rev. Urol. 14, 26\u201337 (2017).","journal-title":"Nat. Rev. Urol."},{"key":"384_CR20","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/jnci\/djm168","volume":"99","author":"HK Tsai","year":"2007","unstructured":"Tsai, H. K., D\u2019Amico, A. V., Sadetsky, N., Chen, M.-H. & Carroll, P. R. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J. Natl Cancer Inst. 99, 1516\u20131524 (2007).","journal-title":"J. Natl Cancer Inst."},{"key":"384_CR21","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.eururo.2014.11.039","volume":"68","author":"C Bosco","year":"2015","unstructured":"Bosco, C. et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur. Urol. 68, 386\u2013396 (2015).","journal-title":"Eur. Urol."},{"key":"384_CR22","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/jamaoncol.2015.4655","volume":"2","author":"DL Hershman","year":"2016","unstructured":"Hershman, D. L. et al. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol. 2, 453\u2013461 (2016).","journal-title":"JAMA Oncol."},{"key":"384_CR23","doi-asserted-by":"crossref","first-page":"e196562","DOI":"10.1001\/jamanetworkopen.2019.6562","volume":"2","author":"R Jayadevappa","year":"2019","unstructured":"Jayadevappa, R. et al. Association between androgen deprivation therapy use and diagnosis of dementia in men with prostate cancer. JAMA Netw. Open 2, e196562\u2013e196562 (2019).","journal-title":"JAMA Netw. Open"},{"key":"384_CR24","doi-asserted-by":"crossref","first-page":"99057","DOI":"10.18632\/oncotarget.21519","volume":"8","author":"C Chen","year":"2017","unstructured":"Chen, C. et al. Comparisons of health-related quality of life among surgery and radiotherapy for localized prostate cancer: a systematic review and meta-analysis. Oncotarget 8, 99057\u201399065 (2017).","journal-title":"Oncotarget"},{"key":"384_CR25","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D\u2019Amico","year":"1998","unstructured":"D\u2019Amico, A. V. et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280, 969\u2013974 (1998).","journal-title":"JAMA"},{"key":"384_CR26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","volume":"17","author":"JL Mohler","year":"2019","unstructured":"Mohler, J. L. et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 17, 479\u2013505 (2019).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"384_CR27","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.juro.2017.11.095","volume":"199","author":"MG Sanda","year":"2018","unstructured":"Sanda, M. G. et al. Clinically localized prostate cancer: AUA\/ASTRO\/SUO Guideline. Part I: risk stratification, shared decision making, and care options. J. Urol. 199, 683\u2013690 (2018).","journal-title":"J. Urol."},{"key":"384_CR28","unstructured":"Mottet, N. et al. EAU\u2013ESTRO\u2013ESUR\u2013SIOG guidelines on prostate cancer (EAU, 2019)."},{"key":"384_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2010.03.001","volume":"58","author":"M Spahn","year":"2010","unstructured":"Spahn, M. et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20ng\/ml: a European multi-institutional study of 712 patients. Eur. Urol. 58, 1\u20137 (2010).","journal-title":"Eur. Urol."},{"key":"384_CR30","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1464-410X.2010.09594.x","volume":"107","author":"J Walz","year":"2011","unstructured":"Walz, J. et al. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int. 107, 765\u2013770 (2011).","journal-title":"BJU Int."},{"key":"384_CR31","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.urology.2010.11.057","volume":"77","author":"R Miocinovic","year":"2011","unstructured":"Miocinovic, R. et al. Avoiding androgen deprivation therapy in men with high-risk prostate cancer: the role of radical prostatectomy as initial treatment. Urology 77, 946\u2013950 (2011).","journal-title":"Urology"},{"key":"384_CR32","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0090-4295(99)80091-0","volume":"45","author":"AW Partin","year":"1995","unstructured":"Partin, A. W. et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 45, 831\u2013838 (1995).","journal-title":"Urology"},{"key":"384_CR33","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0090-4295(01)01441-8","volume":"58","author":"AW Partin","year":"2001","unstructured":"Partin, A. W. et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58, 843\u2013848 (2001).","journal-title":"Urology"},{"key":"384_CR34","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/jnci\/90.10.766","volume":"90","author":"MW Kattan","year":"1998","unstructured":"Kattan, M. W., Eastham, J. A., Stapleton, A. M. F., Wheeler, T. M. & Scardino, P. T. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J. Natl Cancer Inst. 90, 766\u2013771 (1998).","journal-title":"J. Natl Cancer Inst."},{"key":"384_CR35","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/jnci\/djj190","volume":"98","author":"AJ Stephenson","year":"2006","unstructured":"Stephenson, A. J. et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J. Natl Cancer Inst. 98, 715\u2013717 (2006).","journal-title":"J. Natl Cancer Inst."},{"key":"384_CR36","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/01.ju.0000158155.33890.e7","volume":"173","author":"MR Cooperberg","year":"2005","unstructured":"Cooperberg, M. R. et al. The University of California, San Francisco cancer of the prostate risk assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J. Urol. 173, 1938\u20131942 (2005).","journal-title":"J. Urol."},{"key":"384_CR37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/pcan.2013.46","volume":"17","author":"D Sundi","year":"2014","unstructured":"Sundi, D. et al. Very high risk localized prostate cancer: definition and outcomes. Prostate Cancer Prostatic Dis. 17, 57\u201363 (2014).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"384_CR38","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.eururo.2011.11.043","volume":"61","author":"A Briganti","year":"2012","unstructured":"Briganti, A. et al. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. Eur. Urol. 61, 584\u2013592 (2012).","journal-title":"Eur. Urol."},{"key":"384_CR39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2014.01.020","volume":"67","author":"S Joniau","year":"2015","unstructured":"Joniau, S. et al. Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. Eur. Urol. 67, 157\u2013164 (2015).","journal-title":"Eur. Urol."},{"key":"384_CR40","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/diagnostics8030062","volume":"8","author":"AK Angeles","year":"2018","unstructured":"Angeles, A. K., Bauer, S., Ratz, L., Klauck, S. M. & S\u00fcltmann, H. Genome-based classification and therapy of prostate cancer. Diagnostics 8, 62 (2018).","journal-title":"Diagnostics"},{"key":"384_CR41","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2015.05.042","volume":"69","author":"AE Ross","year":"2016","unstructured":"Ross, A. E. et al. Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate- and high-risk men. Eur. Urol. 69, 157\u2013165 (2016).","journal-title":"Eur. Urol."},{"key":"384_CR42","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.eururo.2017.05.009","volume":"72","author":"PL Nguyen","year":"2017","unstructured":"Nguyen, P. L. et al. Ability of a genomic classifier to predict metastasis and prostate cancer-specific mortality after radiation or surgery based on needle biopsy specimens. Eur. Urol. 72, 845\u2013852 (2017).","journal-title":"Eur. Urol."},{"key":"384_CR43","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.eururo.2014.05.039","volume":"67","author":"MR Cooperberg","year":"2015","unstructured":"Cooperberg, M. R. et al. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur. Urol. 67, 326\u2013333 (2015).","journal-title":"Eur. Urol."},{"key":"384_CR44","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1200\/JCO.2016.70.2811","volume":"35","author":"DE Spratt","year":"2017","unstructured":"Spratt, D. E. et al. Individual patient-level meta-analysis of the performance of the Decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease. J. Clin. Oncol. 35, 1991\u20131998 (2017).","journal-title":"J. Clin. Oncol."},{"key":"384_CR45","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.eururo.2014.05.004","volume":"66","author":"EA Klein","year":"2014","unstructured":"Klein, E. A. et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur. Urol. 66, 550\u2013560 (2014).","journal-title":"Eur. Urol."},{"key":"384_CR46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.eururo.2014.11.030","volume":"68","author":"J Cullen","year":"2015","unstructured":"Cullen, J. et al. A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer. Eur. Urol. 68, 123\u2013131 (2015).","journal-title":"Eur. Urol."},{"key":"384_CR47","unstructured":"US Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03070886 (2020)."},{"key":"384_CR48","unstructured":"US Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02783950 (2020)."},{"key":"384_CR49","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ijrobp.2013.10.023","volume":"89","author":"AD Falchook","year":"2014","unstructured":"Falchook, A. D., Salloum, R. G., Hendrix, L. H. & Chen, R. C. Use of bone scan during initial prostate cancer workup, downstream procedures, and associated Medicare costs. Int. J. Radiat. Oncol. Biol. Phys. 89, 243\u2013248 (2014).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"384_CR50","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.eururo.2015.07.029","volume":"70","author":"M de Rooij","year":"2016","unstructured":"de Rooij, M., Hamoen, E. H. J., Witjes, J. A., Barentsz, J. O. & Rovers, M. M. Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis. Eur. Urol. 70, 233\u2013245 (2016).","journal-title":"Eur. Urol."},{"key":"384_CR51","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2967\/jnumed.115.166512","volume":"57","author":"AB Apolo","year":"2016","unstructured":"Apolo, A. B. et al. Prospective study evaluating Na18F PET\/CT in predicting clinical outcomes and survival in advanced prostate cancer. J. Nucl. Med. 57, 886\u2013892 (2016).","journal-title":"J. Nucl. Med."},{"key":"384_CR52","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1097\/01.ju.0000123981.03084.06","volume":"171","author":"S Abuzallouf","year":"2004","unstructured":"Abuzallouf, S., Dayes, I. & Lukka, H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J. Urol. 171, 2122\u20132127 (2004).","journal-title":"J. Urol."},{"key":"384_CR53","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.eururo.2012.02.020","volume":"62","author":"FE Lecouvet","year":"2012","unstructured":"Lecouvet, F. E. et al. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99\u2009m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur. Urol. 62, 68\u201375 (2012).","journal-title":"Eur. Urol."},{"key":"384_CR54","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","volume":"63","author":"AM H\u00f6vels","year":"2008","unstructured":"H\u00f6vels, A. M. et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin. Radiol. 63, 387\u2013395 (2008).","journal-title":"Clin. Radiol."},{"key":"384_CR55","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/1097-0142(19950815)76:4<661::AID-CNCR2820760419>3.0.CO;2-S","volume":"76","author":"GL Davis","year":"1995","unstructured":"Davis, G. L. Sensitivity of frozen section examination of pelvic lymph nodes for metastatic prostate carcinoma. Cancer 76, 661\u2013668 (1995).","journal-title":"Cancer"},{"key":"384_CR56","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2214\/ajr.167.6.8956585","volume":"167","author":"GJ Jager","year":"1996","unstructured":"Jager, G. J., Barentsz, J. O., Oosterhof, G. O., Witjes, J. A. & Ruijs, S. J. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional T1-weighted magnetization-prepared-rapid gradient-echo sequence. Am. J. Roentgenol. 167, 1503\u20131507 (1996).","journal-title":"Am. J. Roentgenol."},{"key":"384_CR57","doi-asserted-by":"crossref","first-page":"772","DOI":"10.2214\/AJR.13.11187","volume":"202","author":"Y Chong","year":"2014","unstructured":"Chong, Y. et al. Value of diffusion-weighted imaging at 3\u2009T for prediction of extracapsular extension in patients with prostate cancer: a preliminary study. Am. J. Roentgenol. 202, 772\u2013777 (2014).","journal-title":"Am. J. Roentgenol."},{"key":"384_CR58","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12149-019-01343-y","volume":"33","author":"S Sheikhbahaei","year":"2019","unstructured":"Sheikhbahaei, S. et al. 18F-NaF-PET\/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies. Ann. Nucl. Med. 33, 351\u2013361 (2019).","journal-title":"Ann. Nucl. Med."},{"key":"384_CR59","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.urology.2017.12.001","volume":"116","author":"MA Bjurlin","year":"2018","unstructured":"Bjurlin, M. A. et al. Imaging the high-risk prostate cancer patient: current and future approaches to staging. Urology 116, 3\u201312 (2018).","journal-title":"Urology"},{"key":"384_CR60","first-page":"331","volume":"40","author":"TM Shoup","year":"1999","unstructured":"Shoup, T. M. et al. Synthesis and evaluation of 18F 1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors. J. Nucl. Med. 40, 331\u2013338 (1999).","journal-title":"J. Nucl. Med."},{"key":"384_CR61","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s00259-016-3383-8","volume":"43","author":"OA Odewole","year":"2016","unstructured":"Odewole, O. A. et al. Recurrent prostate cancer detection with anti-3-[18F]FACBC PET\/CT: comparison with CT. Eur. J. Nucl. Med. Mol. Imaging 43, 1773\u20131783 (2016).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"384_CR62","first-page":"85","volume":"3","author":"DM Schuster","year":"2013","unstructured":"Schuster, D. M. et al. Characterization of primary prostate carcinoma by anti-1-amino-2-[18F]-fluorocyclobutane-1-carboxylic acid (anti-3-[18F] FACBC) uptake. Am. J. Nucl. Med. Mol. Imaging 3, 85\u201396 (2013).","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"384_CR63","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/jjco\/hyv181","volume":"46","author":"H Suzuki","year":"2016","unstructured":"Suzuki, H. et al. Diagnostic performance and safety of NMK36 (trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid)-PET\/CT in primary prostate cancer: multicenter phase IIb clinical trial. Jpn. J. Clin. Oncol. 46, 152\u2013162 (2016).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"384_CR64","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00259-017-3875-1","volume":"45","author":"I Jambor","year":"2018","unstructured":"Jambor, I. et al. Prospective evaluation of 18F-FACBC PET\/CT and PET\/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial). Eur. J. Nucl. Med. Mol. Imaging 45, 355\u2013364 (2018).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"384_CR65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","volume":"41","author":"A Afshar-Oromieh","year":"2014","unstructured":"Afshar-Oromieh, A. et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 41, 11\u201320 (2014).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"384_CR66","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2967\/jnumed.117.197160","volume":"59","author":"PJ Roach","year":"2018","unstructured":"Roach, P. J. et al. The impact of 68Ga-PSMA PET\/CT on management intent in prostate cancer: results of an Australian prospective multicenter study. J. Nucl. Med. 59, 82\u201388 (2018).","journal-title":"J. Nucl. Med."},{"key":"384_CR67","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","volume":"195","author":"T Maurer","year":"2016","unstructured":"Maurer, T. et al. Diagnostic efficacy of 68Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J. Urol. 195, 1436\u20131443 (2016).","journal-title":"J. Urol."},{"key":"384_CR68","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2967\/jnumed.115.154336","volume":"56","author":"SP Rowe","year":"2015","unstructured":"Rowe, S. P. et al. 18F-DCFBC PET\/CT for PSMA-based detection and characterization of primary prostate cancer. J. Nucl. Med. 56, 1003\u20131010 (2015).","journal-title":"J. Nucl. Med."},{"key":"384_CR69","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.juro.2017.07.070","volume":"199","author":"MA Gorin","year":"2018","unstructured":"Gorin, M. A. et al. Prostate specific membrane antigen targeted 18F-DCFPyL positron emission tomography\/computerized tomography for the preoperative staging of high risk prostate cancer: results of a prospective, phase II, single center study. J. Urol. 199, 126\u2013132 (2018).","journal-title":"J. Urol."},{"key":"384_CR70","unstructured":"US Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03803475 (2020)."},{"key":"384_CR71","unstructured":"US Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03204123 (2020)."},{"key":"384_CR72","unstructured":"US Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT03439033 (2020)."},{"key":"384_CR73","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrurol.2016.26","volume":"13","author":"T Maurer","year":"2016","unstructured":"Maurer, T., Eiber, M., Schwaiger, M. & Gschwend, J. E. Current use of PSMA-PET in prostate cancer management. Nat. Rev. Urol. 13, 226\u2013235 (2016).","journal-title":"Nat. Rev. Urol."},{"key":"384_CR74","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman, M. S. et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395, 1208\u20131216 (2020).","journal-title":"Lancet"},{"key":"384_CR75","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.ejca.2005.11.030","volume":"42","author":"H Van Poppel","year":"2006","unstructured":"Van Poppel, H. et al. Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001). Eur. J. Cancer 42, 1062\u20131067 (2006).","journal-title":"Eur. J. Cancer"},{"key":"384_CR76","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.urology.2005.12.003","volume":"67","author":"RK Berglund","year":"2006","unstructured":"Berglund, R. K. et al. Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis. Urology 67, 1253\u20131256 (2006).","journal-title":"Urology"},{"key":"384_CR77","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.urology.2007.02.054","volume":"69","author":"S Loeb","year":"2007","unstructured":"Loeb, S., Smith, N. D., Roehl, K. A. & Catalona, W. J. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology 69, 1170\u20131175 (2007).","journal-title":"Urology"},{"key":"384_CR78","doi-asserted-by":"crossref","first-page":"335.e1","DOI":"10.1016\/j.urolonc.2016.03.002","volume":"34","author":"C Paterson","year":"2016","unstructured":"Paterson, C., Alashkham, A., Lang, S. & Nabi, G. Early oncological and functional outcomes following radical treatment of high-risk prostate cancer in men older than 70 years: a prospective longitudinal study. Urol. Oncol. 34, 335.e1\u2013335.e7 (2016).","journal-title":"Urol. Oncol."},{"key":"384_CR79","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.urolonc.2010.11.018","volume":"31","author":"CG Rogers","year":"2013","unstructured":"Rogers, C. G. et al. Robot assisted radical prostatectomy for elderly patients with high risk prostate cancer. Urol. Oncol. 31, 193\u2013197 (2013).","journal-title":"Urol. Oncol."},{"key":"384_CR80","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/end.2010.0349","volume":"25","author":"G Jayram","year":"2011","unstructured":"Jayram, G. et al. Robotic radical prostatectomy in patients with high-risk disease: a review of short-term outcomes from a high-volume center. J. Endourol. 25, 455\u2013457 (2011).","journal-title":"J. Endourol."},{"key":"384_CR81","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1111\/j.1464-410X.2010.09484.x","volume":"106","author":"CO Wambi","year":"2010","unstructured":"Wambi, C. O. et al. Early oncological outcomes of robot-assisted radical prostatectomy for high-grade prostate cancer. BJU Int. 106, 1739\u20131745 (2010).","journal-title":"BJU Int."},{"key":"384_CR82","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1089\/lap.2008.0344","volume":"19","author":"WS Ham","year":"2009","unstructured":"Ham, W. S., Park, S. Y., Rha, K. H., Kim, W. T. & Choi, Y. D. Robotic radical prostatectomy for patients with locally advanced prostate cancer is feasible: results of a single-institution study. J. Laparoendosc. Adv. Surg. Tech. 19, 329\u2013332 (2009).","journal-title":"J. Laparoendosc. Adv. Surg. Tech."},{"key":"384_CR83","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1089\/end.2009.0388","volume":"23","author":"JT Casey","year":"2009","unstructured":"Casey, J. T., Meeks, J. J., Greco, K. A., Wu, S. D. & Nadler, R. B. Outcomes of locally advanced (T3 or greater) prostate cancer in men undergoing robot-assisted laparoscopic prostatectomy. J. Endourol. 23, 1519\u20131522 (2009).","journal-title":"J. Endourol."},{"key":"384_CR84","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.eururo.2015.06.020","volume":"68","author":"F Abdollah","year":"2015","unstructured":"Abdollah, F. et al. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients. Eur. Urol. 68, 497\u2013505 (2015).","journal-title":"Eur. Urol."},{"key":"384_CR85","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1464-410X.2009.09080.x","volume":"106","author":"G Ploussard","year":"2010","unstructured":"Ploussard, G. et al. Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high-risk prostate cancer. BJU Int. 106, 86\u201390 (2010).","journal-title":"BJU Int."},{"key":"384_CR86","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.urology.2009.11.085","volume":"76","author":"PM Pierorazio","year":"2010","unstructured":"Pierorazio, P. M. et al. Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. Urology 76, 715\u2013721 (2010).","journal-title":"Urology"},{"key":"384_CR87","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1590\/S1677-5538.IBJU.2013.05.05","volume":"39","author":"NJ Harty","year":"2013","unstructured":"Harty, N. J., Kozinn, S. I., Canes, D., Sorcini, A. & Moinzadeh, A. Comparison of positive surgical margin rates in high risk prostate cancer: open versus minimally invasive radical prostatectomy. Int. Braz. J. Urol. 39, 639\u2013648 (2013).","journal-title":"Int. Braz. J. Urol."},{"key":"384_CR88","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.eururo.2012.06.057","volume":"63","author":"S Joniau","year":"2013","unstructured":"Joniau, S. et al. Mapping of pelvic lymph node metastases in prostate cancer. Eur. Urol. 63, 450\u2013458 (2013).","journal-title":"Eur. Urol."},{"key":"384_CR89","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2007.07.035","volume":"53","author":"A Mattei","year":"2008","unstructured":"Mattei, A. et al. The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur. Urol. 53, 118\u2013125 (2008).","journal-title":"Eur. Urol."},{"key":"384_CR90","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/bju.14164","volume":"122","author":"M Altok","year":"2018","unstructured":"Altok, M. et al. Surgeon-led prostate cancer lymph node staging: pathological outcomes stratified by robot-assisted dissection templates and patient selection. BJU Int. 122, 66\u201375 (2018).","journal-title":"BJU Int."},{"key":"384_CR91","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.eururo.2009.03.012","volume":"55","author":"A Briganti","year":"2009","unstructured":"Briganti, A. et al. Pelvic lymph node dissection in prostate cancer. Eur. Urol. 55, 1251\u20131265 (2009).","journal-title":"Eur. Urol."},{"key":"384_CR92","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0022-5347(05)00685-3","volume":"175","author":"TA Masterson","year":"2006","unstructured":"Masterson, T. A. et al. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J. Urol. 175, 1320\u20131325 (2006).","journal-title":"J. Urol."},{"key":"384_CR93","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1464-410X.2012.11765.x","volume":"112","author":"KH Kim","year":"2013","unstructured":"Kim, K. H. et al. Extended vs standard lymph node dissection in robot-assisted radical prostatectomy for intermediate- or high-risk prostate cancer: a propensity-score-matching analysis. BJU Int. 112, 216\u2013223 (2013).","journal-title":"BJU Int."},{"key":"384_CR94","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1089\/lap.2011.0516","volume":"22","author":"JH Jung","year":"2012","unstructured":"Jung, J. H. et al. Extended pelvic lymph node dissection including internal iliac packet should be performed during robot-assisted laparoscopic radical prostatectomy for high-risk prostate cancer. J. Laparoendosc. Adv. Surg. Tech. 22, 785\u2013790 (2012).","journal-title":"J. Laparoendosc. Adv. Surg. Tech."},{"key":"384_CR95","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.eururo.2016.12.003","volume":"72","author":"N Fossati","year":"2017","unstructured":"Fossati, N. et al. The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review. Eur. Urol. 72, 84\u2013109 (2017).","journal-title":"Eur. Urol."},{"key":"384_CR96","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.juro.2014.08.091","volume":"193","author":"SI Tyritzis","year":"2015","unstructured":"Tyritzis, S. I. et al. Thromboembolic complications in 3,544 patients undergoing radical prostatectomy with or without lymph node dissection. J. Urol. 193, 117\u2013125 (2015).","journal-title":"J. Urol."},{"key":"384_CR97","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.juro.2013.10.062","volume":"191","author":"MK Tollefson","year":"2014","unstructured":"Tollefson, M. K., Karnes, R. J., Rangel, L., Carlson, R. & Boorjian, S. A. Blood type, lymphadenectomy and blood transfusion predict venous thromboembolic events following radical prostatectomy with pelvic lymphadenectomy. J. Urol. 191, 646\u2013651 (2014).","journal-title":"J. Urol."},{"key":"384_CR98","unstructured":"US Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01812902 (2018)."},{"key":"384_CR99","unstructured":"US Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01555086 (2017)."},{"key":"384_CR100","doi-asserted-by":"crossref","first-page":"574.e11","DOI":"10.1016\/j.urolonc.2019.06.005","volume":"37","author":"R Jayadevappa","year":"2019","unstructured":"Jayadevappa, R., Lee, D. I., Chhatre, S., Guzzo, T. J. & Malkowicz, S. B. Comparative effectiveness of treatments for high-risk prostate cancer patients. Urol. Oncol. 37, 574.e11\u2013574.e18 (2019).","journal-title":"Urol. Oncol."},{"key":"384_CR101","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.eururo.2018.10.032","volume":"75","author":"S Berg","year":"2019","unstructured":"Berg, S. et al. Comparative effectiveness of radical prostatectomy versus external beam radiation therapy plus brachytherapy in patients with high-risk localized prostate cancer. Eur. Urol. 75, 552\u2013555 (2019).","journal-title":"Eur. Urol."},{"key":"384_CR102","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bju.14780","volume":"124","author":"CA Reichard","year":"2019","unstructured":"Reichard, C. A. et al. Radical prostatectomy or radiotherapy for high- and very high-risk prostate cancer: a multidisciplinary prostate cancer clinic experience of patients eligible for either treatment. BJU Int. 124, 811\u2013819 (2019).","journal-title":"BJU Int."},{"key":"384_CR103","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jama.2018.0587","volume":"319","author":"AU Kishan","year":"2018","unstructured":"Kishan, A. U. et al. Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9\u201310 prostate cancer. JAMA 319, 896\u2013905 (2018).","journal-title":"JAMA"},{"key":"384_CR104","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1200\/JCO.2017.75.9134","volume":"36","author":"RD Ennis","year":"2018","unstructured":"Ennis, R. D., Hu, L., Ryemon, S. N., Lin, J. & Mazumdar, M. Brachytherapy-based radiotherapy and radical prostatectomy are associated with similar survival in high-risk localized prostate cancer. J. Clin. Oncol. 36, 1192\u20131198 (2018).","journal-title":"J. Clin. Oncol."},{"key":"384_CR105","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","volume":"375","author":"FC Hamdy","year":"2016","unstructured":"Hamdy, F. C. et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N. Engl. J. Med. 375, 1415\u20131424 (2016).","journal-title":"N. Engl. J. Med."},{"key":"384_CR106","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/bju.14987","volume":"125","author":"RJ Bryant","year":"2020","unstructured":"Bryant, R. J. et al. The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression. BJU Int. 125, 506\u2013514 (2020).","journal-title":"BJU Int."},{"key":"384_CR107","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.eururo.2019.10.030","volume":"77","author":"DE Neal","year":"2020","unstructured":"Neal, D. E. et al. Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received. Eur. Urol. 77, 320\u2013330 (2020).","journal-title":"Eur. Urol."},{"key":"384_CR108","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.eururo.2020.02.009","volume":"77","author":"TJ Wilt","year":"2020","unstructured":"Wilt, T. J. et al. Radical prostatectomy or observation for clinically localized prostate cancer: extended follow-up of the prostate cancer intervention versus observation trial (PIVOT). Eur. Urol. 77, 713\u2013724 (2020).","journal-title":"Eur. Urol."},{"key":"384_CR109","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1056\/NEJMoa1807801","volume":"379","author":"A Bill-Axelson","year":"2018","unstructured":"Bill-Axelson, A. et al. Radical prostatectomy or watchful waiting in prostate cancer \u2014 29-year follow-up. N. Engl. J. Med. 379, 2319\u20132329 (2018).","journal-title":"N. Engl. J. Med."},{"key":"384_CR110","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/21681805.2018.1520295","volume":"52","author":"J Stranne","year":"2018","unstructured":"Stranne, J. et al. SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer. Scand. J. Urol. 52, 313\u2013320 (2018).","journal-title":"Scand. J. Urol."},{"key":"384_CR111","doi-asserted-by":"crossref","first-page":"163.e7","DOI":"10.1016\/j.urolonc.2014.11.018","volume":"33","author":"A Briganti","year":"2015","unstructured":"Briganti, A. et al. Natural history of surgically treated high-risk prostate cancer. Urol. Oncol. 33, 163.e7\u2013163.e13 (2015).","journal-title":"Urol. Oncol."},{"key":"384_CR112","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1464-410X.2005.05394.x","volume":"95","author":"JF Ward","year":"2005","unstructured":"Ward, J. F., Slezak, J. M., Blute, M. L., Bergstralh, E. J. & Zincke, H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 95, 751\u2013756 (2005).","journal-title":"BJU Int."},{"key":"384_CR113","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.juro.2006.03.093","volume":"176","author":"BS Carver","year":"2006","unstructured":"Carver, B. S., Bianco, F. J., Scardino, P. T. & Eastham, J. A. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J. Urol. 176, 564\u2013568 (2006).","journal-title":"J. Urol."},{"key":"384_CR114","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.urology.2011.05.021","volume":"78","author":"G Ploussard","year":"2011","unstructured":"Ploussard, G. et al. Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification. Urology 78, 607\u2013613 (2011).","journal-title":"Urology"},{"key":"384_CR115","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1464-410X.2007.07269.x","volume":"101","author":"SA Boorjian","year":"2008","unstructured":"Boorjian, S. A. et al. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8\u201310 cancers. BJU Int. 101, 299\u2013304 (2008).","journal-title":"BJU Int."},{"key":"384_CR116","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/cncr.22116","volume":"107","author":"PJ Bastian","year":"2006","unstructured":"Bastian, P. J. et al. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer 107, 1265\u20131272 (2006).","journal-title":"Cancer"},{"key":"384_CR117","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3109\/00365599.2011.637956","volume":"46","author":"S Joniau","year":"2012","unstructured":"Joniau, S., Hsu, C.-Y., Gontero, P., Spahn, M. & Van Poppel, H. Radical prostatectomy in very high-risk localized prostate cancer: long-term outcomes and outcome predictors. Scand. J. Urol. Nephrol. 46, 164\u2013171 (2012).","journal-title":"Scand. J. Urol. Nephrol."},{"key":"384_CR118","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.eururo.2007.10.008","volume":"53","author":"O Yossepowitch","year":"2008","unstructured":"Yossepowitch, O. et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur. Urol. 53, 950\u2013959 (2008).","journal-title":"Eur. Urol."},{"key":"384_CR119","doi-asserted-by":"crossref","first-page":"234.e13","DOI":"10.1016\/j.urolonc.2015.11.018","volume":"34","author":"P Dell\u2019Oglio","year":"2016","unstructured":"Dell\u2019Oglio, P. et al. Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer. Urol. Oncol. 34, 234.e13\u2013234.e19 (2016).","journal-title":"Urol. Oncol."},{"key":"384_CR120","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2012.08.054","volume":"63","author":"A Briganti","year":"2013","unstructured":"Briganti, A. et al. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. Eur. Urol. 63, 693\u2013701 (2013).","journal-title":"Eur. Urol."},{"key":"384_CR121","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.urology.2016.03.028","volume":"93","author":"A Gordon","year":"2016","unstructured":"Gordon, A. et al. Quantification of long-term stability and specific relief of lower urinary tract symptoms (LUTS) after robot-assisted radical prostatectomy. Urology 93, 97\u2013103 (2016).","journal-title":"Urology"},{"key":"384_CR122","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1470-2045(18)30780-0","volume":"20","author":"A Downing","year":"2019","unstructured":"Downing, A. et al. Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study. Lancet Oncol. 20, 436\u2013447 (2019).","journal-title":"Lancet Oncol."},{"key":"384_CR123","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/j.juro.2008.08.015","volume":"180","author":"AK Wu","year":"2008","unstructured":"Wu, A. K., Cooperberg, M. R., Sadetsky, N. & Carroll, P. R. Health related quality of life in patients treated with multimodal therapy for prostate cancer. J. Urol. 180, 2415\u20132422 (2008).","journal-title":"J. Urol."},{"key":"384_CR124","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1001\/jama.296.19.2329","volume":"296","author":"IM Thompson","year":"2006","unstructured":"Thompson, I. M. et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296, 2329\u20132335 (2006).","journal-title":"JAMA"},{"key":"384_CR125","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1200\/JCO.2008.18.9563","volume":"27","author":"T Wiegel","year":"2009","unstructured":"Wiegel, T. et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02\/AUO AP 09\/95. J. Clin. Oncol. 27, 2924\u20132930 (2009).","journal-title":"J. Clin. Oncol."},{"key":"384_CR126","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(05)67101-2","volume":"366","author":"M Bolla","year":"2005","unstructured":"Bolla, M. et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366, 572\u2013578 (2005).","journal-title":"Lancet"},{"key":"384_CR127","volume":"4","author":"WL Hwang","year":"2018","unstructured":"Hwang, W. L. et al. Comparison between adjuvant and early-salvage postprostatectomy radiotherapy for prostate cancer with adverse pathological features. JAMA Oncol. 4, e175230 (2018).","journal-title":"JAMA Oncol."},{"key":"384_CR128","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1001\/jama.299.23.2760","volume":"299","author":"BJ Trock","year":"2008","unstructured":"Trock, B. J. et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299, 2760\u20132769 (2008).","journal-title":"JAMA"},{"key":"384_CR129","doi-asserted-by":"crossref","first-page":"v851","DOI":"10.1093\/annonc\/mdz394.042","volume":"30","author":"C Parker","year":"2019","unstructured":"Parker, C. et al. Timing of radiotherapy (RT) after radical prostatectomy (RP): first results from the RADICALS RT randomised controlled trial (RCT) [NCT00541047]. Ann. Oncol. 30, v851\u2013v934 (2019).","journal-title":"Ann. Oncol."},{"key":"384_CR130","doi-asserted-by":"crossref","first-page":"v883","DOI":"10.1093\/annonc\/mdz394.041","volume":"30","author":"CL Vale","year":"2019","unstructured":"Vale, C. L. et al. Adjuvant or salvage radiotherapy for the treatment of localised prostate cancer? A prospectively planned aggregate data meta-analysis. Ann. Oncol. 30, v883 (2019).","journal-title":"Ann. Oncol."},{"key":"384_CR131","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1464-410X.1994.tb09196.x","volume":"74","author":"AG Aprikian","year":"1994","unstructured":"Aprikian, A. G. et al. Experience with neoadjuvant diethylstilboestrol and radical prostatectomy in patients with locally advanced prostate cancer. Br. J. Urol. 74, 630\u2013636 (1994).","journal-title":"Br. J. Urol."},{"key":"384_CR132","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1464-410X.1995.tb07389.x","volume":"75","author":"ML Cher","year":"1995","unstructured":"Cher, M. L., Shinohara, K., Breslin, S., Vapnek, J. & Carroll, P. R. High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer. Br. J. Urol. 75, 771\u2013777 (1995).","journal-title":"Br. J. Urol."},{"key":"384_CR133","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0090-4295(00)00914-6","volume":"57","author":"PE Clark","year":"2001","unstructured":"Clark, P. E. et al. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 57, 281\u2013285 (2001).","journal-title":"Urology"},{"key":"384_CR134","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.urology.2004.01.040","volume":"63","author":"R Dreicer","year":"2004","unstructured":"Dreicer, R. et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 63, 1138\u20131142 (2004).","journal-title":"Urology"},{"key":"384_CR135","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-05-0299","volume":"11","author":"PG Febbo","year":"2005","unstructured":"Febbo, P. G. et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin. Cancer Res. 11, 5233\u20135240 (2005).","journal-title":"Clin. Cancer Res."},{"key":"384_CR136","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/cncr.22897","volume":"110","author":"C Magi-Galluzzi","year":"2007","unstructured":"Magi-Galluzzi, C., Zhou, M., Reuther, A. M., Dreicer, R. & Klein, E. A. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer 110, 1248\u20131254 (2007).","journal-title":"Cancer"},{"key":"384_CR137","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1464-410X.2007.06760.x","volume":"100","author":"T Prayer-Galetti","year":"2007","unstructured":"Prayer-Galetti, T. et al. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU Int. 100, 274\u2013280 (2007).","journal-title":"BJU Int."},{"key":"384_CR138","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.juro.2008.04.012","volume":"180","author":"KN Chi","year":"2008","unstructured":"Chi, K. N. et al. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J. Urol. 180, 565\u2013570 (2008).","journal-title":"J. Urol."},{"key":"384_CR139","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/cncr.24092","volume":"115","author":"J Vuky","year":"2009","unstructured":"Vuky, J. et al. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. Cancer 115, 784\u2013791 (2009).","journal-title":"Cancer"},{"key":"384_CR140","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bju.12676","volume":"116","author":"JL Silberstein","year":"2015","unstructured":"Silberstein, J. L. et al. Long-term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high-risk prostate cancer. BJU Int. 116, 50\u201356 (2015).","journal-title":"BJU Int."},{"key":"384_CR141","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/s41391-017-0009-6","volume":"21","author":"RR McKay","year":"2018","unstructured":"McKay, R. R. et al. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer Prostatic Dis. 21, 364\u2013372 (2018).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"384_CR142","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","volume":"16","author":"K Fizazi","year":"2015","unstructured":"Fizazi, K. et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol. 16, 787\u2013794 (2015).","journal-title":"Lancet Oncol."},{"key":"384_CR143","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.urology.2003.09.052","volume":"62","author":"JA Eastham","year":"2003","unstructured":"Eastham, J. A., Kelly, W. K., Grossfeld, G. D., Small, E. J. & Cancer and Leukemia Group B. Cancer and leukemia group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 62, 55\u201362 (2003).","journal-title":"Urology"},{"key":"384_CR144","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1200\/JCO.2019.37.15_suppl.5079","volume":"37","author":"JA Eastham","year":"2019","unstructured":"Eastham, J. A. et al. CALGB 90203 (Alliance): radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC). J. Clin. Oncol. 37, 5079\u20135079 (2019).","journal-title":"J. Clin. Oncol."},{"key":"384_CR145","unstructured":"Masic, S. SUO 2019: an update on CALGB 90203, radical prostatectomy with or without neoadjuvant chemohormonal therapy in men with clinically localized, high-risk prostate cancer, the PUNCH study (UroToday, 2019)."},{"key":"384_CR146","doi-asserted-by":"crossref","first-page":"TPS383","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS383","volume":"38","author":"M-E Taplin","year":"2020","unstructured":"Taplin, M.-E. et al. PROTEUS: a randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC). J. Clin. Oncol. 38, TPS383 (2020).","journal-title":"J. Clin. Oncol."},{"key":"384_CR147","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.eururo.2018.01.012","volume":"73","author":"GM Ahlgren","year":"2018","unstructured":"Ahlgren, G. M. et al. Docetaxel versus surveillance after radical prostatectomy for high-risk prostate cancer: results from the prospective randomised, open-label phase 3 Scandinavian Prostate Cancer Group 12 trial. Eur. Urol. 73, 870\u2013876 (2018).","journal-title":"Eur. Urol."},{"key":"384_CR148","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.eururo.2019.12.020","volume":"77","author":"DW Lin","year":"2020","unstructured":"Lin, D. W. et al. Veterans affairs cooperative studies program study #553: chemotherapy after prostatectomy for high-risk prostate carcinoma: a phase III randomized study. Eur. Urol. 77, 563\u2013572 (2020).","journal-title":"Eur. Urol."},{"key":"384_CR149","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1111\/j.1464-410X.2011.10628.x","volume":"109","author":"BB McGuire","year":"2012","unstructured":"McGuire, B. B. et al. Outcomes in patients with Gleason score 8\u201310 prostate cancer: relation to preoperative PSA level. BJU Int. 109, 1764\u20131769 (2012).","journal-title":"BJU Int."},{"key":"384_CR150","doi-asserted-by":"crossref","unstructured":"Zehnder, P. in Keys to Successful Orthotopic Bladder Substitution (ed. Studer, U. E.) 93\u201397 (Springer, 2014).","DOI":"10.1007\/978-3-319-12382-0_6"}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41585-020-00384-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41585-020-00384-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41585-020-00384-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:25:49Z","timestamp":1684621549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-020-00384-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,10]]},"references-count":150,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["384"],"URL":"https:\/\/doi.org\/10.1038\/s41585-020-00384-7","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,10]]},"assertion":[{"value":"28 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.F.C. declares that he is a consultant and adviser for Blue Earth Diagnostics and Janssen and has received research funding from Janssen. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}